Azo-Standard, Baridium, Geridium,
Phenazo, Prodium, Pyridiate, Pyridium, Pyridium Plus, Urodine, Urogesic, UTI Relief
Therapeutic: nonopioid analgesics
Pharmacologic: urinary tract analgesics
Provides relief from the following urinary tract symptoms, which may occur in association with infection or following urologic procedures: Pain, Itching, Burning, Urgency, Frequency.
Acts locally on the urinary tract mucosa to produce analgesic or local anesthetic effects. Has no antimicrobial activity. Therapeutic Effects: Diminished urinary tract discomfort.
Adverse Reactions/Side Effects
CNS: headache, vertigo. GI: hepatotoxicity, nausea. GU: bright-orange urine, renal failure. Derm: rash. Hemat: hemolytic anemia, methemoglobinemia.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Be alert for signs of liver toxicity, including anorexia, abdominal pain, severe nausea and vomiting, yellow skin or eyes, skin rashes, flu-like symptoms, and muscle/joint pain. Report these signs to the physician immediately.
Monitor signs of hemolytic anemia (unusual fatigue, shortness of breath, dizziness, headache, pale skin, chest pain, coldness in hands and feet)
and methemoglobinemia (bluish coloring of the skin, lips fingernails; headache; shortness of breath; lack of energy). Notify physician immediately if these signs occur.
Monitor signs of renal failure, including decreased urine output, increased blood pressure, muscle cramps/twitching, edema/weight gain from fluid retention, yellowish brown skin, and confusion that progresses to seizures and coma. Report these signs to the physician immediately.
Assess pain and other urinary tract symptoms (burning, itching, urinary frequency) to document whether this drug is successful in helping manage the patient's pain.
Assess vertigo that might affect gait, balance, and other functional activities. Report balance problems and functional limitations to the physician and nursing staff, and caution the patient and family/caregivers to guard against falls and trauma.
Absorption: Appears to be well absorbed following oral administration.
Distribution: Unknown. Small amounts cross the placenta.
Metabolism and Excretion: Rapidly excreted unchanged in the urine.
TIME/ACTION PROFILE (urinary analgesia)
|ROUTE ||ONSET ||PEAK ||DURATION |
|PO ||unknown ||5–6 hr ||6–8 hr |
Contraindicated in: Hypersensitivity; Glomerulonephritis; Severe hepatitis, uremia, or renal failure; Renal insufficiency; G6PD deficiency.
Use Cautiously in: Hepatitis; Pregnancy or lactation (safety not established).
Drug-Drug: None significant.
PO (Adults): 200 mg tid for 2 days.
PO (Children): 4 mg/kg tid for 2 days.